{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:21:03Z","timestamp":1794277263762,"version":"4.9.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014835","name":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"","doi-asserted-by":"publisher","award":["Ricerca Corrente RC 2022\/2024, Project - \u201cTheory enhancing\u201d: \"Valutazione dell\u2019espressione dell\u2019enzima indoleamina 2,3-diossigenasi-1 (IDO) in associazione ad altri biomarcatori tissutali, genomici e bioumorali quali fattori prognostici e predittivi di risposta al trattamento immunoterapico con anticorpi monoclonali anti-PD-1 in pazienti con carcinoma endometriale ricorrente o avanzato con deficit di riparazione del mismatch del DNA (MMRd) o elevata instabilit\u00e0 dei microsatelliti (MSI-H)\"."],"award-info":[{"award-number":["Ricerca Corrente RC 2022\/2024, Project - \u201cTheory enhancing\u201d: \"Valutazione dell\u2019espressione dell\u2019enzima indoleamina 2,3-diossigenasi-1 (IDO) in associazione ad altri biomarcatori tissutali, genomici e bioumorali quali fattori prognostici e predittivi di risposta al trattamento immunoterapico con anticorpi monoclonali anti-PD-1 in pazienti con carcinoma endometriale ricorrente o avanzato con deficit di riparazione del mismatch del DNA (MMRd) o elevata instabilit\u00e0 dei microsatelliti (MSI-H)\"."]}],"id":[{"id":"10.13039\/501100014835","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Immunotherapy is acquiring a primary role in treating endometrial cancer (EC) with a relevant benefit for many patients. Regardless, patients progressing during immunotherapy or those who are resistant represent an unmet need. The mechanisms of immune resistance and escape need to be better investigated. Here, we review the major mechanisms of immune escape activated by the indolamine 2,3-dioxygenase 1 (IDO1) pathway in EC and focus on potential therapeutic strategies based on IDO1 signaling pathway control. IDO1 catalyzes the first rate-limiting step of the so-called \u201ckynurenine (Kyn) pathway\u201d, which converts the essential amino acid\n                    <jats:sc>l<\/jats:sc>\n                    -tryptophan into the immunosuppressive metabolite\n                    <jats:sc>l<\/jats:sc>\n                    -kynurenine. Functionally, IDO1 has played a pivotal role in cancer immune escape by catalyzing the initial step of the Kyn pathway. The overexpression of IDO1 is also associated with poor prognosis in EC. These findings can lead to advantages in immunotherapy-based approaches as a rationale for overcoming the immune escape. Indeed, besides immune checkpoints, other mechanisms, including the IDO enzymes, contribute to the EC progression due to the immunosuppression induced by the tumor milieu. On the other hand, the IDO1 enzyme has recently emerged as both a promising therapeutic target and an unfavorable prognostic biomarker. This evidence provides the basis for translational strategies of immune combination, whereas IDO1 expression would serve as a potential prognostic biomarker in metastatic EC.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.953115","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T05:37:36Z","timestamp":1662097056000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Anna","family":"Passarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Chiara","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jole","family":"Ventriglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Gherardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Iannacone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Setola","family":"Venanzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giosu\u00e8","family":"Scognamiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_280503","article-title":"A review of immune checkpoint blockade therapy in endometrial cancer","volume":"40","author":"Green","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20042","article-title":"Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity","volume":"8","author":"Mittica","year":"2017","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.03.022","article-title":"Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer","volume":"114","author":"de Jong","year":"2009","journal-title":"Gynecol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.6004\/jadpro.2022.13.1.4","article-title":"Emerging treatment options for advanced or recurrent endometrial cancer","volume":"13","author":"Halla","year":"2022","journal-title":"J Adv Pract Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.9.1363","article-title":"Inhibition of T cell proliferation by macrophage tryptophan catabolism","volume":"189","author":"Munn","year":"1999","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0991","article-title":"Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model","volume":"14","author":"Yoshida","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2015.2714","article-title":"Expression of immune checkpoint molecules in endometrial carcinoma","volume":"10","author":"Liu","year":"2015","journal-title":"Exp Ther Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.10.001","article-title":"Indoleamine 2,3 dioxygenase and metabolic control of immune responses","volume":"34","author":"Munn","year":"2013","journal-title":"Trends Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2077","article-title":"Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells","volume":"12","author":"Pallotta","year":"2011","journal-title":"Nat Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0137","article-title":"Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues","volume":"3","author":"Th\u00e9ate","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4077","article-title":"Toward the identification of a tolerogenic signature in IDO-competent dendritic cells","volume":"107","author":"Orabona","year":"2006","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810278105","article-title":"SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis","volume":"105","author":"Orabona","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1113873109","article-title":"Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase","volume":"109","author":"Pilotte","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1014465107","article-title":"Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism","volume":"107","author":"Nguyen","year":"2010","journal-title":"PNAS"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1246-0","article-title":"The roles of mast cells in anti-cancer immunity","volume":"61","author":"Dalton","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev-immunol-020711-075024","article-title":"Regulation of immune responses by mTOR","volume":"30","author":"Powell","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903919106","article-title":"Infectious tolerance via the consumption of essential amino acids and mTOR signaling","volume":"106","author":"Cobbold","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.1172638","article-title":"Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response","volume":"324","author":"Sundrud","year":"2009","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.790","article-title":"Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase","volume":"8","author":"Keller","year":"2012","journal-title":"Nat Chem Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.11.6752","article-title":"The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells","volume":"176","author":"Fallarino","year":"2006","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31911","article-title":"Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature tregs via indoleamine 2,3-dioxygenase","volume":"117","author":"Sharma","year":"2007","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1117736109","article-title":"Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase","volume":"109","author":"Ravishankar","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1504276112","article-title":"The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity","volume":"112","author":"Ravishankar","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00946-13","article-title":"GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology","volume":"34","author":"Liu","year":"2014","journal-title":"Mol Cell Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0039-1","article-title":"Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas","volume":"31","author":"Mills","year":"2018","journal-title":"Mod Pathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31822017fb","article-title":"Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer","volume":"21","author":"de Jong","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000815","article-title":"IDO induces expression of a novel tryptophan transporter in mouse and human tumor cells","volume":"187","author":"Silk","year":"2011","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.05.034","article-title":"Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma","volume":"126","author":"de Jong","year":"2012","journal-title":"Gynecol Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.1158\/1078-0432.CCR-07-0942","article-title":"Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma","volume":"13","author":"Riesenberg","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1966","article-title":"Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells","volume":"12","author":"Brandacher","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.07.015","article-title":"Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma","volume":"115","author":"Inaba","year":"2009","journal-title":"Gynecol Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.02.028","article-title":"Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy","volume":"117","author":"Inaba","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603477","article-title":"Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer","volume":"95","author":"Ino","year":"2006","journal-title":"Br J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-008-0395-1","article-title":"Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma","volume":"134","author":"Pan","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1159\/000492849","article-title":"The clinicopathological and prognostic significance of IDO1 expression in human solid tumors: evidence from a systematic review and meta-analysis","volume":"49","author":"Yu","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4144","article-title":"Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival","volume":"14","author":"Ino","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/ijgc-2021-003017","article-title":"Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9\/LEAP-001","volume":"32","author":"Marth","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1777625","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124077","article-title":"IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma","volume":"129","author":"Blair","year":"2019","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J Exp Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nm1196","article-title":"Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy","volume":"11","author":"Muller","year":"2005","journal-title":"Nat Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1158\/2326-6066.CIR-16-0400","article-title":"Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance","volume":"5","author":"Hennequart","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-030419-033635","article-title":"Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma","volume":"4","author":"Van den Eynde","year":"2020","journal-title":"Ann Rev Cancer Biol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-015-0094-9","article-title":"Targeting the indoleamine 2,3-dioxygenase pathway in cancer","volume":"3","author":"Moon","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3170","article-title":"Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated anti-tumor immunity","volume":"70","author":"Gu","year":"2010","journal-title":"Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25393","article-title":"Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA-mismatch repair profile","volume":"9","author":"Meireson","year":"2018","journal-title":"Oncotarget"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001099","article-title":"Indoleamine-2,3-dioxygenase in non-small cell lung cancer: a targetable mechanism of immune resistance frequently coexpressed with PD-L1","volume":"42","author":"Volaric","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000000494","article-title":"Targetable immune regulatory molecule expression in high-grade serous ovarian carcinomas in African American women: a study of PD-L1 and IDO in 112 cases from the African American cancer epidemiology study (AACES)","volume":"38","author":"Mills","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3241","article-title":"Molecular subtype not immune response drives outcomes in endometrial carcinoma","volume":"25","author":"Talhouk","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-3-S2-O7","article-title":"Preliminary results from a phase I\/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers","volume":"3","author":"Gangadhar","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat plus pembrolizumab in patients with advanced solid tumors: Phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.956","article-title":"Retifanlimab (INCMGA00012) in patients with recurrent MSI-h or dMMR endometrial cancer: results from the POD1UM-101 study","volume":"9","author":"Berton","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2092","article-title":"Kynurenine is an endothelium-derived relaxing factor produced during inflammation","volume":"16","author":"Wang","year":"2010","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.953115\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T05:37:39Z","timestamp":1662097059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.953115\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":67,"alternative-id":["10.3389\/fimmu.2022.953115"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.953115","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"article-number":"953115"}}